Vanzacaftor, Tezacaftor, and Deutivacaftor
Brand Names: Alyftrek
Methodology & AI Transparency ⓘ
Vanzacaftor, Tezacaftor, and Deutivacaftor Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 10 mg/1 / 50 mg/1 Tablet, Film Coated and 4 mg/1 / 20 mg/1 Tablet, Film Coated and manufactured/labeled by Vertex Pharmaceuticals Incorporated (NDC 51167-121, 51167-135), Vanzacaftor, Tezacaftor, and Deutivacaftor operates within oral-route cystic fibrosis transmembrane conductance regulator potentiator treatment algorithms requiring prescription authorization.
- 2 Real-world patient consensus: 83% patient "Worth It" rating across 22 anonymous logs for Vanzacaftor, Tezacaftor, and Deutivacaftor (RxNorm RXN-51167121-3011).
- 3 Typical cash cost range: Dispensing cost comparison spans $80.59 mail/discount cash up to $197.45 uninsured retail (federal NADAC $1.7800).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Vanzacaftor, Tezacaftor, and Deutivacaftor: nausea (8.1%), headache (8%), dizziness (6.6%).
Ask our AI Specialists anything about Vanzacaftor, Tezacaftor, and Deutivacaftor
Vanzacaftor, Tezacaftor, and Deutivacaftor Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 10 mg/1 / 50 mg/1 Tablet, Film Coated and 4 mg/1 / 20 mg/1 Tablet, Film Coated and manufactured/labeled by Vertex Pharmaceuticals Incorporated (NDC 51167-121, 51167-135), Vanzacaftor, Tezacaftor, and Deutivacaftor operates within oral-route cystic fibrosis transmembrane conductance regulator potentiator treatment algorithms requiring prescription authorization.
Delivered via 10 mg/1 / 50 mg/1 Tablet, Film Coated and 4 mg/1 / 20 mg/1 Tablet, Film Coated (oral-route; NDC 51167-121, 51167-135), Vanzacaftor, Tezacaftor, and Deutivacaftor mediates cystic fibrosis transmembrane conductance regulator potentiator physiological effects manufactured/labeled by Vertex Pharmaceuticals Incorporated with dose-dependent receptor occupancy and systemic clearance.
Systemic exposure to Vanzacaftor, Tezacaftor, and Deutivacaftor reflects Estimated 75%–87% oral systemic absorption for Vanzacaftor, Tezacaftor, and Deutivacaftor absorption kinetics and phase i/ii hepatic conjugation of vanzacaftor, tezacaftor, and deutivacaftor coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 9–14 hours terminal plasma half-life for Vanzacaftor, Tezacaftor, and Deutivacaftor half-life window (peak plasma concentration (tmax) reached 1–4 hours post-dose for vanzacaftor, tezacaftor, and deutivacaftor response profile).
Dosing protocols (10 mg/1 / 50 mg/1 Tablet, Film Coated or 4 mg/1 / 20 mg/1 Tablet, Film Coated) balance efficacy (83.00% patient satisfaction across 22 logs) against nausea (8.1% of reports), headache (8% of reports), dizziness (6.6% of reports), with strict avoidance in known hypersensitivity to vanzacaftor, tezacaftor, and deutivacaftor or structurally related cystic fibrosis transmembrane conductance regulator potentiator compounds; concomitant contra-labeled cyp/transporter therapies during active vanzacaftor, tezacaftor, and deutivacaftor administration.
Avoid overlapping cystic fibrosis transmembrane conductance regulator potentiator prescriptions alongside Vanzacaftor, Tezacaftor, and Deutivacaftor to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Vanzacaftor, Tezacaftor, and Deutivacaftor dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Vanzacaftor, Tezacaftor, and Deutivacaftor or structurally related cystic fibrosis transmembrane conductance regulator potentiator compounds
- Concomitant contra-labeled CYP/transporter therapies during active Vanzacaftor, Tezacaftor, and Deutivacaftor administration
Logged Side-Effect Incidence (22 Reports)
Vanzacaftor, Tezacaftor, and Deutivacaftor Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vanzacaftor, Tezacaftor, and Deutivacaftor)
Human clinical trial evidence for Vanzacaftor, Tezacaftor, and Deutivacaftor is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Vanzacaftor, Tezacaftor, and Deutivacaftor Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.7800/unit (~$53.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $197.45 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $80.59 / mo | View logs ↓ |
Vanzacaftor, Tezacaftor, and Deutivacaftor Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vanzacaftor, Tezacaftor, and Deutivacaftor RxNorm Concept ID | RXN-51167121-3011 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.7800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $197.45 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $80.59 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vanzacaftor, Tezacaftor, and Deutivacaftor Patient Community, Cohort Filters & Dosage Logs
Cross-verified Vanzacaftor, Tezacaftor, and Deutivacaftor (cystic fibrosis transmembrane conductance regulator potentiator) monograph synthesizing RxNorm RXN-51167121-3011, openFDA FAERS signals, and $80.59–$197.45 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vanzacaftor, Tezacaftor, and Deutivacaftor community threads and patient logs by age, biological sex, dosage, and treatment duration.